DeRen Huang

Memorial Hospital of South Bend — United States

Medicine · Health Sciences

36h-index4.9kcitations64works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Sclerosis Research Studies(13), Myasthenia Gravis and Thymoma(12), T-cell and B-cell Immunology(9), Monoclonal and Polyclonal Antibodies Research(7), Neuroinflammation and Neurodegeneration Mechanisms(7)

Publications63 total

Five Years of Ublituximab in Relapsing Multiple Sclerosis: Additional Results from Open-label Extension of ULTIMATE I and II Studies (P11-1.006)
Neurology·2025
Histidine-rich glycoprotein modulates neutrophils and thrombolysis-associated hemorrhagic transformation
EMBO Molecular Medicine·2024· 10 citedOpen Access
Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs (P7-3.011)
Neurology·2023· 3 cited
Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies (P6-3.015)
Neurology·2023· 3 cited
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
New England Journal of Medicine·2022· 170 cited
Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations From the Phase 3 ULTIMATE I and II Studies (P5-4.009)
Neurology·2022· 2 cited
Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010)
Neurology·2022· 2 cited
Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Sclerosis (RMS) (P1-1.Virtual)
Neurology·2022· 1 cited
Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) (P6-4.005)
Neurology·2022
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
The Lancet Neurology·2021· 178 citedOpen Access
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet Neurology·2021· 108 cited
Efficacy and safety of ublituximab versus teriflunomide in relapsing multiple sclerosis: Results of the Phase 3 ULTIMATE I and II trials (4494)
Neurology·2021· 3 cited
Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis (4845)
Neurology·2020
Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 mAb, in Patients with RMS (1167)
Neurology·2020
Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results
Multiple Sclerosis Journal - Experimental Translational and Clinical·2019· 5 citedOpen Access
Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
Patient Preference and Adherence·2018· 5 citedOpen Access
Treatment Satisfaction Increased over One Year When MS Patients Switched from an Interferon Beta Therapy to Peginterferon Beta-1a (P2.394)
Neurology·2017
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
Translational Stroke Research·2016· 103 citedOpen Access
Selective Sphingosine-1-Phosphate Receptor 1 Modulation Attenuates Experimental Intracerebral Hemorrhage
Stroke·2016· 88 cited
Real-World Patient Retention and Satisfaction on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis; Results from PREFERMS (P6.167)
Neurology·2016· 1 cited
page 1 of 4Next →

Frequent Co-authors

Richard M. Ransohoff(13), Ann Kari Lefvert(10), Sibyl Wray(9), Ritva Pirskanen(9), Fu‐Dong Shi(7), Daniel Wynn(7), Derrick Robertson(7), Enrique Álvarez(7), Ricardo Giscombe(7), Lawrence Steinman(6), Hans‐Peter Hartung(6), Peiqing Qian(6), Krzysztof Selmaj(6), Koby Mok(6), Jenna A. Bosco(6), Jintang Wang(5), Michael Weiss(5), Yihua Zhou(5), Toby T. He(4), Sean A. Power(4)